(MENAFN- EIN Presswire) Leading Pharmaceutical companies are advancing the AAV vector gene therapy pipeline and its future growth potential. LAS VEGAS , NV, UNITED STATES, February 7, 2025 ...

Organoids were cultured from healthy donor iPSC sources and differentiated using the human iPSC-derived Cerebral Organoid ...

Researchers have demonstrated, for the first time in the world using mice, the ability to overcome significant challenges in ...

Researchers are enhancing the best features of AAV capsids and overcoming their limitations to accelerate gene-based therapies.

Gene therapy is usually reserved for severe and ... These rats were randomly selected to receive AAVlac (a recombinant AAV vector expressing ß-galactosidase 18) or PBS vehicle.

The nano-complexes released the loaded-AAV intracellularly ... approach to viral vector treatments, which are currently limited by neutralizing antibodies. Gene therapy is a treatment method ...

BioViva’s journey in gene therapy began with its use of an adeno-associated virus (AAV) vector. The company’s lead gene therapy, BV-702, is AAV-based and is in preclinical development for ...

Patients with CTNNB1 Syndrome will benefit from this joint effort to develop and manufacture a new AAV investigational gene therapy ... a clinically validated vector that is expected to enter ...

Viralgen and Axovia Therapeutics are set to form a partnership to progress the development and manufacturing of an adeno-associated virus vector serotype 9 (AAV9)-based gene therapy for retinal ...

OXB (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces the appointment of Jefferies International Limited ("Jefferies") as its Joint Corporate Broker and Joint ...